Adam Laponis, an officer of Twist Bioscience Corp, filed a Form 144 notice on November 16, 2026, disclosing a proposed sale of 6,359 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ:TWST.
Key Highlights
- Shares proposed for sale: 6,359 shares of Twist Bioscience common stock, with an aggregate market value of $659,354.54, according to the filing.
- Source of shares: The shares were acquired on November 12, 2026, through restricted stock vesting from the issuer, with compensation listed as the nature of payment.
- Approximate sale date: November 16, 2026, via Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
- Total shares outstanding: The filing states 62,707,424 shares outstanding.
- Prior sales in past 3 months: Laponis sold 1,965 shares on August 21, 2026 (gross proceeds $273,265.47); 8,057 shares on October 2, 2026 (gross proceeds $1,521,836.78); and 2,462 shares on October 9, 2026 (gross proceeds $384,822.66).
- Tax-related purpose noted: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
Adam Laponis Files Rule 144 Notice for Restricted Stock Vesting Sale
According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 16, 2026, Adam Laponis, identified as an officer of Twist Bioscience Corp (NASDAQ:TWST), intends to sell 6,359 shares of the company's common stock. The filing lists the aggregate market value of the proposed sale at $659,354.54. The broker named in the filing is Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917.
The filing discloses that the 6,359 shares were acquired on November 12, 2026, through restricted stock vesting from the issuer, with the nature of payment listed as compensation. The filing includes a remark that the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution." Twist Bioscience Corp is listed with SEC File Number 001-38720 and is headquartered at 681 Gateway Blvd., South San Francisco, California 94080.
As required under Rule 144, the filing also discloses Laponis's sales of Twist Bioscience common stock during the prior three months. Those transactions included 1,965 shares sold on August 21, 2026, for gross proceeds of $273,265.47; 8,057 shares sold on October 2, 2026, for gross proceeds of $1,521,836.78; and 2,462 shares sold on October 9, 2026, for gross proceeds of $384,822.66. The filing was signed by Jared Cook as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Adam Laponis.
What Was Disclosed
Twist Bioscience officer Adam Laponis filed a Form 144 notice on November 16, 2026, proposing to sell 6,359 shares of common stock acquired through restricted stock vesting, with the aggregate market value reported as $659,354.54, partly to cover tax obligations from a vested equity award.



Please wait processing your request...